Abstract. Five osteosarcoma (OS) cell lines, 37 OS tumors and 9 corresponding non-neoplastic samples were genotyped by Affymetrix 10 K 2.0 SNP array. Regions of high level amplification and homozygous deletion were identified and validated by quantitative PCR and FISH. Certain recurrent cytogenetic alterations were more frequent in recurrent/ metastatic than in primary OS. These included deletion of 6q14.1, 6q16.2-q22.31, and 8p23.2-p12, amplification of 8q21.12, 8q22.3-q24.3 and 17p12, and loss of heterozygosity (LOH) at 2q24.3-q31.2, 5q11.2, 6p21.31-p21.1, 6q14.1-q16.2, 8p22-p12, 9q22.1, 10q21.1-q22.1, 10q23.31-q24.1, 12q15-q21.1 and 21q21.2-q21.3. Most of the LOH calls were associated with deletion, but a subset of them was associated with normal or increased copy number (CN). A consensus 3q13.31 deletion localized to a region within the limbic systemassociated membrane protein (LSAMP) gene was also identified. The FISH evaluations demonstrated highlylocalized homozygous or heterozygous LSAMP deletions in 6 of 11 primary OS. qRT-PCR evaluations of the two major alternative LSAMP transcripts demonstrated reduced expression of 1b isoform transcript in each of three OS with LSAMP exon 1b deletion. Further, the 1a isoform transcripts in these same OS had either reduced expression or a premature termination codon in LSAMP exon 2. This SNP genotyping study identified chromosomal aberrations associated with disease progression in OS and disclosed LSAMP as a novel tumor suppressor gene in OS. The study also demonstrated that CN and LOH analyses were able to detect distinct subsets of genetic abnormalities in OS.
Introduction
Previous studies have implicated several genetic mechanisms in osteosarcoma (OS) tumorigenesis. These include cell cycle alterations resulting from genomic changes of TP53, RB1 and MDM2; perturbation of cell senescence pathways resulting from telomere dysfunction; alterations in cell death/cytokine pathways resulting from FAS dysregulation (1); and upregulation of EZR in metastatic OS (2) . Genetic complexity is a hallmark of high grade OS, and multiple genomic amplifications and deletions have been demonstrated by karyotyping studies (3) and by molecular cytogenetic assays (4) (5) (6) (7) (8) (9) (10) .
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Identification of chromosomal aberrations associated
with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma been applied for studies of chromosomal aberrations in cancer (11) (12) (13) (14) (15) (16) (17) (18) (19) . SNP arrays detect DNA copy number (CN) changes and cancer-specific loss of heterozygosity (LOH) in a genomewide fashion.
In this study, we performed high-throughput SNP genotyping of 5 OS cell lines, 37 OS tumors and 9 matched non-neoplastic samples and identified chromosomal aberrations associated with disease progression in OS. A consensus 3q13.31 deletion localized to a region within the limbic system-associated membrane protein (LSAMP) gene was also identified and was associated with either reduced expression or presence of a premature termination codon of LSAMP transcripts.
Materials and methods

Primary tumors and cell lines. This study was approved by the Institutional Review Boards of Taipei Veterans General
Hospital and Brigham and Women's Hospital. SNP assays were performed using genomic DNAs isolated from 37 snapfrozen OS in 36 ethnic Chinese patients (from Taipei Veterans General Hospital), matched peripheral blood lymphocytes in 9 of the patients and 5 OS cell lines. Fluorescence in situ hybridization (FISH) and quantitative reverse transcription-PCR (qRT-PCR) were performed on an independent group of 11 frozen untreated OS from a second institution (Brigham and Women's Hospital). Informed consent was obtained from each patient. In order to minimize false-negative SNP data, the study inclusion criteria required that each OS specimen be composed of at least 70% neoplastic cells on histological review. OS cell lines (MG63, G292, U2OS, SaOS2 and HOS) and an osteoblast cell line (hFOB 1.19) were obtained from ATCC.
SNP array and dChip SNP analysis. SNP assays were performed at Microarray and Gene Expression Analysis Core Facility of the VGH-Yang Ming Genome Research Center using the GeneChip ® Human Mapping 10K Array Xba 142 2.0 (GeneChip ® Mapping 10K 2.0 Array) (Affymetrix, Inc., Santa Clara, CA) according to previously described methods (20) and the manufacturer's protocol. Genomic CN alterations and LOH changes were analyzed using dChip software (http://biosun1.harvard.edu/complab/dchip/), as previously described (11, 21, 22) . Mapping of SNP locations to cytogenetic bands was obtained by integration of datasets from Affymetrix and University of California Santa Cruz (UCSC) Genome Browser hg 17 (http://genome.ucsc.edu). All samples used in analysis had SNP call rates >85%. The invariant set normalization method (23) was used to normalize all arrays at the probe intensity level to an array with median intensity. After normalization, a model-based method was used to obtain the signal values for each SNP in each array (24) .
Normalized intensities of the SNP loci obtained from 9 peripheral blood lymphocyte samples were used as the baseline to estimate the CN of the corresponding SNP loci in the tumor samples. From raw signal data, the inferred CN of each SNP locus was estimated by applying the hidden Markov model (HMM) (11) . An inferred copy step of 0.335 was used as modified from Zhao et al (19) , based on the possibility of diploidy or triploidy in the cancer cells.
The SNP calls of a matched pair of peripheral blood lymphocyte and tumor samples were combined to obtain the observed LOH calls. For unpaired tumor samples or cell lines, regions with LOH call were identified using an HMM method developed by Beroukhim et al (22) . Regions of CN-neutral LOH were identified by setting LOH with CN 2±0.335.
Quantitative PCR (qPCR) confirmation of SNP findings. All primers were designed with Primer Express 3.0 software (Applied Biosystems Foster City, CA) using default parameters, with modified minimum amplicon length requirements (85 bp) and with requirement of maximum GC content of 40% for the five last 3' end nucleotides. The primer sequences are shown in Table I . PCR reactions were performed, as previously described (25) . DNA content was normalized to that of long interspersed elements (LINE1), a repetitive element for which CNs per haploid genome are similar both in normal or neoplastic cells (26) . CN changes per haploid genome were calculated using the formula 2*2 (Nt-Nline)-(Tt-Tline) , where Nt and Nline are the threshold cycle numbers observed for the experimental primer and LINE1 primer, respectively, in the normal DNA samples, and Tt and Tline are the threshold cycle numbers observed for the experimental primer and LINE1 primer, respectively, in the test DNA samples (26) . In normal cells the expected CN of each gene is 2. PCR reactions with each primer set were performed in triplicate, and calculated CN changes per haploid genome were averaged.
FISH. FISH was performed using methods described previously (27, 28) . FISH probes were made from bacterial artificial chromosome (BAC) clones -containing genomic segments of interest -identified using Ensembl Genome Browser http://www.ensembl.org/ and UCSC Genome Browser http://genome.ucsc.edu. BACs were obtained from the RPCI-11 BAC library or CTD clone collection (29, 30) , digoxigenin-labeled using the Random Prime DNA Labeling System (Invitrogen) according to the manufacturer's protocol and detected with FITC (green). Biotin-labeled probe to the chromosome 3 centromeric region was purchased from Zymed/ Invitrogen and was detected with rhodamine (red). BAC chromosomal locations were corroborated by FISH in normal lymphocyte metaphases. OS FISH assays were scored only in neoplastic nuclei, and the relative CN per nucleus was defined as (#BAC signals/#centromeric signals) x 2. Samples where >50% of nuclei had relative FISH CN of ≤1 or 0, respectively, were considered to have heterozygous or homozygous deletions.
RNA preparation, qRT-PCR, RT-PCR and sequencing. Total RNAs were isolated from cell lines and frozen tumors using TRIzol ® Reagent (Invitrogen), according to the manufacturer's instructions. Reverse transcription was performed from 1 μg RNA using the Bio-Rad iScript™ cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). mRNA CN for both LSAMP isoforms and for the ß-actin housekeeping gene were determined by qRT-PCR using iQ SYBR-Green supermix and a MyiQ single-color real-time PCR detection system (Bio-Rad Laboratories). Primers to amplify type 1a and type 1b LSAMP isoforms were designed based on full length LSAMP 1b isoform mRNA (Genbank accession number NM_002338) and cDNA sequence BI199955 covering exon 1a (31) , so that both primer pairs shared reverse primer within exon 4 (5'-AAATTCCCTTCCAGTTGGTGTAA GGT-3') and forward primers within exons 1a (5'-GACCTA CTGGCTGCACAGCGTCT-3') or 1b (5'-GTTCAGCCGGA TCGGAAACAGT-3'). ß-actin (forward primer 5'-CACTGC CCTGGCACCCAGCACA-3' and reverse primer 5'-AGAG GACTGGGCCATTCTCCTT-3') levels were used to normalize the investigated samples, and hFOB 1.19 was used as baseline comparator (32) . Cycling conditions were as follows: 95˚C for 3 min and then 50 cycles at 95˚C for 10 sec, 62˚C for 30 sec and 68˚C for 1 min. Gene expression levels were calculated, as described previously (33) . For RT-PCR and sequencing of 1a isoforms, forward primer 5'-AGGACC TACTGGCTGCACAGCGTC-3' and reverse primer 5'-CCC TCATCATAGACATCCACCTTCTGGA-3' were used. Cycling conditions were as follows: 95˚C for 5 min and then 50 cycles at 95˚C for 15 sec, 65˚C for 30 sec and 68˚C for 1 min.
Statistical analysis. Statistical comparisons were performed using SPSS 12.0 software. Chi-square tests or Fisher exact tests were used to evaluate the correlations between chromosomal aberrations and tumor status (primary vs. recurrent/ metastatic). A P-value <0.05 was considered statistically significant. Fig. 1 . Frequent chromosomal regions of CN gain (regions >5 kb containing at least three consecutive SNPs with average inferred CN ≥3 occurring in 6 or more cases) and CN loss (regions >5 kb containing at least three consecutive SNPs with average inferred CN ≤1.5 occurring in 6 or more cases) are summarized in Table III . The size of regions of frequent aberrations ranged from <0.91 to >44.08 Mb, the number of SNP spanning these regions ranged from 4 to 186 and the number of gene contained with these regions ranged from 3 to 246. Most frequent (>20%) CN gain was found over 8q22.2-q24.22 and 17p, and most frequent CN loss was identified at 2q33.2-q33.3, 2q36.3-q37.3, 3p21.2 and 3q13.31.
Results
Clinicopathological characteristics.
High-level amplifications, defined as regions >5 kb containing at least three consecutive SNPs with average inferred CN ≥6 in two or more specimens, were identified at chromosome bands 4q12, 6p21.2-p21.1, 7p22.2, 8q24.11, 11q14.2, 12q14.1, 12q15, 17p12 and 21q21.1. Homozygous deletions, defined as regions >5 kb containing at least three consecutive SNPs with average inferred CN ≤0.67 in two or more cases, with at least one case having an inferred CN ≤0.34, were identified at chromosome bands 3q13.31, 7q35 and 9p21.3. CN alterations for genes in these regions were verified by qPCR (Table IV) , and were consistent with the SNP dChip findings, although gene amplifications were saturated at a lower level when appraised by dChip compared to qPCR. Thus, dChip inferred CN of ≥6 was found to represent actual (qPCR) locus CN ranging from 6.17 to 40 (Table IV) .
The LOH analyses are summarized in Fig. 1 . Chromosomal regions associated with frequent LOH (>30% of cases) Table I . Primer sequences for genomic quantitative PCR.
included 3p, 6q, 8p, 9p, 10q and 13q. Although most of these LOH events corresponded to physical deletions, 28% of LOH events appeared to result from CN-neutral LOH. CN-neutral LOH regions were frequently seen (>60% of LOH were CN-neutral LOH) at 1p, 1q, 2p23-p16, 2q32.3-q33.1, 3q29, 4q13.3, 7q31.1-q31.2, 9q32-q33, 11p11.2-p11.12, 11q, 12p12.1-p11.21, 14q21, 15q, 16q23.1-q24.3 and 20q12.
Identifications of chromosomal aberrations associated with recurrent/metastatic OS. As shown in Fig. 2 (Table VI) . Among these, the 6q, 8p, and 10q LOH events generally resulted from CN losses (deletions). However, a Table II . Clinicopathological characteristics of 36 OS patients. 
OST, osteoblastic; CHO, chondroblastic; FIB, fibroblastic; TEL, telangiectatic; OSTBA, osteoblastoma-like.
a Same patients, different tumors.
subset of LOH events was CN-neutral, such as the 2q LOH in case 34T ( Fig. 3 and (Fig. 3 and Table VI ). CN changes in these three cases were confirmed by qPCR (Table IV) .
Evaluation of the novel deletion region 3q13.31. A highlylocalized region extending from 117.39 to 118.54 Mb at 3q13.31 was identified as a novel deletion region by SNP analysis (Figs. 1 and 4 ). This region of deletion is within the LSAMP gene, which is the only known gene in this region. LSAMP is transcribed in a centromeric direction and two known human isoforms are resulted from alternative use of exon 1b (genomic LSAMP isoform 1b spanning 117.01-117.64 Mb) or exon 1a (genomic LSAMP isoform 1a spanning 117.01-119.20 Mb) (31) (Fig. 4D) . Three cell lines, G292, MG63 and HOS, had highly-localized LSAMP deletions by SNP array (Table IV and Fig. 4A-C Table V for details. deletions, respectively, but lacked RP11-33E19 deletion (Fig. 5) . (Fig. 6A) .
Confirmation of localized LSAMP deletion in primary OSs
The genes for LSAMP isoforms 1a and 1b differ only in their signaling peptides (31) . Therefore we implemented a qRT-PCR strategy using a single exon 4 reverse primer with exon 1a or 1b-specific forward primers to detect the alternative LSAMP transcripts (Fig. 6A) . The primary OS (ST98-0878 and ST98-0626), as described above, with heterozygous LSAMP FISH deletions affecting exon 1b, and the HOS cell line with homozygous deletion of exon 1b, all had expected low expression of LSAMP 1b (Fig. 6B) . In addition, ST98-0878 also had low LSAMP 1a expression, most likely explained by the large heterozygous deletion (extending from 117.46 to 119.24 Mb) involving LSAMP exon 1a in that case. However, ST98-0626 and HOS, which had deletions limited to the 117.46 to 118.13 Mb regions, had high LSAMP 1a expression (Fig. 6C) . Representative figures of FISH results are shown in Fig. 7 .
Demonstration of a truncated LSAMP 1a transcript with premature stop codon in HOS and ST98-0626. RT-PCR
analyses of LSAMP transcript 1a, performed using primers in exon 1a and exon 2, revealed a 308 bp expressed sequence in hFOB 1.19, MG63 and G292, whereas HOS cells expressed a 229 bp sequence, and ST98-0626 expressed both the 229 and 308 bp sequences (Fig. 8A) . Sequencing analyses showed that the 308 bp fragment resulted from the splicing of exon 1a to the 75th bp of exon 1b, which was in turn spliced to exon 2. Table III . Regions of frequent copy number gain or loss. 
-----------------------------------------------------------------------------------------------------
a -----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------
a Including known and hypothetical genes. Table IV . Regions of high amplification and homozygous deletion detected by SNP arrays and qPCR of candidate genes. ----------------------------------------------------------------------------------------------------- However, the 229 bp fragment resulted from the direct splicing of exon 1a to exon 2, creating a premature stop codon (Fig. 8B-D) .
-----------------------------------------------------------------------------------------------------
genes ----------------------------------------------------------------------------------------------------
Discussion
In the present study, we performed a high-resolution genomewide genotyping of OS using SNP array and disclosed a full picture of chromosomal aberrations in OS. We also identified highly amplified regions ranging in size from 32 Kb to 3.48 Mb and homozygous deletions ranging from 60 to 910 Kb, which were confirmed by qPCR (Table IV) . Among these regions, several (and associated candidate genes) have been reported in previous studies, such as 4q12 (KIT and PDGFRA) (34, 35) , 6p21.1 (CDC5L) (36), 12q15 (MDM2) (1), 17p12 (COPS3) (37-39) and 9p21.3 (CDKN2A) (1). However, novel recurrent chromosomal aberrations were also identified, including 7p22.2 (SDK1), 21q21.1 (BTG3) and 3q13.31 (LSAMP).
CN gains of 8q and 17p12 were associated with disease progression. Gain over 8q has been implicated previously in disease progression of OS (9) and other cancers (40, 41) . In this study, we not only confirmed this finding, but also localized the minimal amplification regions to 8q21.12 and 8q22.3-q24.3. These regions are similar to those revealed in studies of disease progression in prostate (40) and gastroesophageal junction adenocarcinoma (41). Amplification of 17p12 was previously identified by OS genotyping (38) . COPS3, a candidate oncogene within this region, was amplified and overexpressed in OS (37) and increased CN of COPS3 was associated with unfavorable prognosis in OS (39) . In the present study, recurrent/metastatic tumors were associated with 17p12 CN gain and qPCR confirmed that COPS3 was the most likely candidate within this region (Table IV) .
CN losses at 6q14.1, 6q16.2-q22.31 and 8p23.2-p12 were more frequently demonstrated in recurrent/metastatic OS. Deletion 6q was associated with metastasis in insulinoma (42) , and deletions 6q14 and 6q16-q23 have been reported as recurrent cytogenetic aberrations in OS (43, 44) . Likewise, previous studies have shown an association of deletion 8p with disease progression in hepatocellular carcinoma (45) and colon cancer (46) . These regions may harbor candidate metastasis suppressors and deserve further studies.
Distinct genetic mechanisms could cause LOH, with different resultant CN changes (11). Point mutation followed by hemizygous deletion could lead to CN reductions. These regions often harbor tumor suppressor genes. On the other hand, mutation with subsequent mitotic recombination or gene conversion will not lead to CN changes (11) . CN-neutral LOH has been identified in various human cancers (13) (14) (15) (16) 47, 48) , and usually implies tumor suppressor events (11, 47) . However, sometime it may be associated with activating mutations, such as those identified in myeloid malignancy (16, 49) .
SNP arrays detected both CN changes and LOH and could help in discriminating different underlying mechanisms of LOH by combining CN analysis. In this study, we identified chromosomal regions with frequent LOH at 3p, 6q, 8p, 9p, 10q and 13q, which generally resulted from the classical deletions INTERNATIONAL JOURNAL OF ONCOLOGY 35: 775-788, 2009 783 Table V . Chromosomal copy number aberrations associated with progression in OS. Table VI . Regions with LOH call associated with progression in OS. 
CN, copy number; R/M, recurrent/metastatic tumor. Reduced CN, indicates whether >50% of LOH calls in that region are associated with copy number decrease. with reduced gene dosage. However, we found that 28% of LOH events were not associated with CN alterations. Moreover, we identified regions with LOH calls associated with increased CN. These regions have been reported in colon cancer (14) and are often associated with allele-specific amplification of oncogenes (17) . In our study, it was interesting that the regions with LOH calls over 12q15 in case 26T contained MDM2, a well-known oncogene in OS (Table IV) (1). We have identified several CN-neutral or CN-increased regions with LOH calls associated with OS disease progression, which warrant further investigation. In order to identify chromosomal regions with high-level amplifications and homozygous deletions by SNP array, we adopted the criteria of Zhao et al (19) , with modifications. This approach highlighted a novel deletion within the LSAMP gene region over cytoband 3q13.31. LSAMP is a putative tumor suppressor gene, which is downregulated in human renal (50) and ovarian (51) cancers. Silencing LSAMP expression in human aortic smooth muscle cells (SMCs) substantially increased SMCs proliferation (52) . LSAMP is a member of the IgLON immunoglobulin subfamily of glycosylphosphatidylinositol-anchored cell adhesion molecules comprised of LSAMP (53) , opioid binding protein/cell adhesion moleculelike neurotrimin (OPCML) (54, 55) and neuronal growth regulator 1 (NEGR1) (56) . OPCML exhibits functional characteristics of a tumor suppressor gene in ovarian cancer in vitro and in vivo models and is underexpressed in 83% of sporadic ovarian cancers (57) .
Our studies revealed two types of 3q13.31 deletions in OS (Fig. 6A) . Type 1 deletions were extremely localized within the 118.05-118.13 Mb region; whereas Type 2 deletions involved a larger region extending from 117.46 to 118.13 Mb. Both Type 1 and Type 2 deletions were shown to be somatic in nature, as they were not found in matched non-neoplastic DNAs from several patients. There was no demonstrable correlation between Type 1 deletion and expression levels of LSAMP 1a or 1b transcripts and therefore the functional relevance of these small deletions remains to be determined. On the other hand, OS cell lines and primary tumors with Type 2 deletions featured low LSAMP 1b expression, presumably resulting from deletion of LSAMP exon 1b. Notably, two OS with Type 2 deletions (ST98-0626 and HOS) featured relatively strong expression of LSAMP 1a transcript. However, RT-PCR and sequencing demonstrated that these LSAMP 1a transcripts were aberrant, because the underlying exon 1b deletion engenders splicing of exon 1a directly to exon 2, creating a shift of the reading frame and a resultant exon 2 premature truncation. In sum, the Type 2 LSAMP deletions are inactivating, being associated with substantial down-regulation of the LSAMP 1b transcript and with either reduced expression or presence of a premature termination codon of LSAMP 1a transcripts.
In summary, this study revealed novel chromosomal aberrations in OS and identified cytogenetic changes associated with recurrent/metastatic behavior. The study also demonstrated that CN and LOH analyses detect distinct subsets of genetic abnormalities in OS. This genomic profiling in OS revealed a novel highly-localized 3q13.31 deletion and has thereby implicated LSAMP as an OS tumor suppressor.
